Asha Therapeutics Selected as a BLUE KNIGHT™ Company by Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA)

Trending...
CINCINNATI, Ohio, Sept. 22, 2023 ~ Asha Therapeutics, a biopharmaceutical company that is revolutionizing the traditional multi-year drug discovery process, has been selected as a BLUE KNIGHT™ company. This joint initiative between Johnson & Johnson Innovation - JLABS and the Biomedical Advanced Research and Development Authority (BARDA) is dedicated to the acceleration of transformative technology and science that will enable a swift and targeted response to evolving threats to public health and safety.

The selection of Asha Therapeutics recognizes the potential of its proprietary PRISM™ molecular design technology platform and innovative science to transform traditional drug development. In contrast to current AI-driven systems of drug discovery that screen millions of existing compounds, the PRISMTM Platform builds custom de novo compounds for specific disease targets. PRISMTM can produce clinic-ready drugs within months, compared with traditional drug discovery that takes years due to time intensive screening and chemical optimization.

More on Boston Chron
Dr. Craig Blackstone M.D., Ph.D., a member of Asha's Board of Directors and Chair of Asha Therapeutics' Scientific Advisory Board, commented on the selection: "The selection of Asha Therapeutics as a BLUE KNIGHT™ awardee highlights the power of its proprietary PRISM™ platform to dramatically accelerate drug development for previously intractable targets, largely considered undruggable. PRISM™'s demonstrated ability to successfully drug almost any target of interest is what has impressed me the most." He went on to say that Asha has proven ability to build a portfolio of assets with disease indications including ALS, Parkinson's Disease, ME/CFS and Long Covid, and Colorectal Cancer in a matter of months, demonstrating compelling efficacy and safety in animal models.

Dr. Bradlee Heckmann, Asha's Scientific Co-Founder and Chief Scientific Officer also commented on the selection: "Asha is honored to be selected as a BLUE KNIGHTTM company...Asa has successfully used PRISMTM to rapidly design development candidates that have the extraordinary promise of becoming curative therapies that will transform patient outcomes." He went on to say they are excited to leverage the capabilities of Asha's PRISMTM technology in order to enable a rapid response to risks to public health and safety in partnership with Johnson & Johnson Innovation - JLABS and BARDA.

More on Boston Chron
Asha Therapeutics has been selected as a BLUE KNIGHTTM company in recognition for its potential in transforming traditional drug development through its proprietary PRISM™ molecular design technology platform. This joint initiative between Johnson & Johnson Innovation - JLABS and BARDA is dedicated towards accelerating transformative technology for public health safety risks. With this selection comes great promise for patients suffering from devastating illnesses who may benefit from curative therapies designed by Asha's platform in the near future.
Filed Under: Business

Show All News | Report Violation

0 Comments